million
case
viral
communityacquir
pneumonia
occur
everi
million
children
million
adult
molecular
diagnost
test
greatli
increas
uwnderstand
role
virus
pneumonia
fi
nding
indic
incid
viral
pneumonia
underestim
children
respiratori
syncyti
viru
rhinoviru
human
metapneumoviru
human
bocaviru
parainfl
uenza
virus
agent
identifi
ed
frequent
develop
develop
countri
dual
viral
infect
common
third
children
evid
viralbacteri
coinfect
adult
virus
put
caus
agent
third
case
communityacquir
pneumonia
particular
infl
uenza
virus
rhinovirus
coronavirus
bacteria
continu
predomin
role
adult
pneumonia
presenc
viral
epidem
commun
patient
age
speed
onset
ill
symptom
biomark
radiograph
chang
respons
treatment
help
diff
erenti
viral
bacteri
pneumonia
howev
clinic
algorithm
exist
distinguish
clearli
caus
pneumonia
clear
consensu
reach
whether
patient
obviou
viral
communityacquir
pneumonia
need
treat
antibiot
apart
neuraminidas
inhibitor
pneumonia
caus
infl
uenza
virus
clear
role
use
specifi
c
antivir
treat
viral
communityacquir
pneumonia
infl
uenza
vaccin
avail
specifi
c
prevent
measur
studi
need
better
understand
caus
pathogenesi
communityacquir
pneumonia
furthermor
region
diff
erenc
caus
pneumonia
investig
particular
obtain
data
develop
countri
pneumonia
common
ill
continu
major
killer
young
children
develop
countri
elderli
peopl
develop
countri
mani
microorgan
associ
pneumonia
attent
turn
import
virus
pathogen
widespread
introduct
haemophilu
infl
uenza
type
b
pneumococc
conjug
vaccin
immunis
programm
led
specul
grow
predomin
virus
caus
childhood
pneumonia
emerg
sever
acut
respiratori
syndrom
sar
avian
infl
uenza
viru
pandem
infl
uenza
viru
reemphasis
import
role
respiratori
virus
caus
sever
pneumonia
new
respiratori
virusessuch
human
metapneumoviru
coronavirus
human
bocavirushav
discov
past
decad
importantli
avail
molecular
diagnost
assay
pcr
greatli
increas
abil
detect
characteris
epidemiolog
respiratori
viru
infect
find
previou
studi
convent
virolog
diagnost
techniqu
use
like
underestim
role
virus
pneumonia
pathogen
seminar
review
viral
communityacquir
pneumonia
immunocompet
children
adult
focus
studi
use
modern
molecular
diagnost
techniqu
accord
estim
million
case
pneumonia
record
everi
year
million
peopl
die
ill
account
total
mortal
million
peopl
highest
incid
aris
children
younger
year
adult
older
year
fi
gure
develop
countri
incid
could
fi
time
higher
develop
region
children
million
episod
pneumonia
record
annual
million
present
develop
countri
million
children
younger
year
die
pneumonia
million
case
childhood
communityacquir
pneumonia
report
yearli
develop
countri
mortal
declin
strikingli
rare
canadian
studi
admiss
childhood
pneumonia
took
place
studi
period
death
record
one
death
comorbid
condit
mortal
per
million
previous
healthi
young
adult
record
uk
usa
alon
econom
burden
communityacquir
pneumonia
estim
us
billion
annual
laboratori
diagnosi
viral
pneumonia
reli
detect
viru
viral
antigen
upperrespiratori
specimen
eg
nasopharyng
aspir
lowerrespiratori
sampl
eg
induc
sputum
cultur
immunofl
uoresc
microscopi
measur
search
pubm
origin
research
review
commentari
term
pneumonia
children
adult
pneumonia
aetiolog
viral
pneumonia
pneumonia
virus
name
specifi
c
respiratori
virus
pneumonia
date
languag
restrict
includ
paid
special
attent
report
publish
sinc
molecular
diagnost
introduc
also
search
person
databas
refer
gather
past
year
manual
scan
refer
select
report
select
author
antibodi
pair
serum
sampl
introduct
pcr
increas
abil
detect
respiratori
virus
includ
diffi
cult
cultur
least
virus
associ
communityacquir
pneumonia
panel
despit
technolog
advanc
establish
caus
pneumonia
remain
challeng
specimen
lowerrespiratori
tract
hard
obtain
distinguish
possibl
prolong
shed
colonis
infect
diffi
cult
diagnosi
viral
pneumonia
relianc
test
nasopharyng
specimen
present
challeng
detect
viru
nasopharynx
could
repres
coincident
upperrespiratori
infect
pneumonia
pathogen
measur
background
preval
asymptomat
nasopharyng
viral
infect
control
group
might
help
clarifi
size
diagnost
issu
popul
level
approach
use
rare
aetiolog
studi
furthermor
research
focus
patient
admit
hospit
therefor
fi
nding
might
repres
mildtomoder
diseas
sever
diff
erent
type
specimen
upper
lower
airway
use
aetiolog
studi
communityacquir
pneumonia
includ
nasopharyng
aspir
wash
swab
nasopharynx
nose
throat
combin
nasopharyg
throat
swab
expector
induc
sputum
tracheal
aspir
bronchoalveolar
lavag
lung
punctur
recoveri
viru
fl
uctuat
accord
specimen
type
probabl
account
variabl
fi
nding
studi
studi
caus
viral
pneumonia
use
upperrespiratori
specimen
test
virus
children
nasopharyng
aspir
gener
deem
specimen
choic
nasal
nasopharyng
mucu
sampl
gather
respiratori
virus
note
mucu
sampl
obtain
nasopharyng
aspir
children
respiratori
infect
obtain
aspir
howev
unpleas
requir
suction
devic
nasal
swab
taken
steril
cotton
swab
depth
cm
compar
sensit
nasopharyng
aspir
cultur
major
respiratori
virus
except
respiratori
syncyti
viru
flock
swab
nylon
fi
bre
perpendicular
fashion
prefer
mani
clinician
conveni
use
similar
sensit
nasopharyng
aspir
detect
pcr
respiratori
virus
adult
nasopharyng
swab
higher
sensit
throat
swab
less
sensit
nasopharyng
wash
transnas
nasopharyng
fl
ock
swab
also
high
viru
detect
rate
adult
lowerrespiratori
specimen
obviou
advantag
establish
caus
pneumonia
come
site
infect
howev
obtain
reliabl
specimen
contamin
fl
ora
upper
airway
diffi
cult
induc
sputum
specimen
use
paediatr
pneumonia
studi
although
assur
specimen
repres
lowerrespiratori
tract
challeng
highqual
specimen
obtain
thorac
needl
aspir
techniqu
adopt
wide
safeti
concern
despit
low
complic
rate
gener
pcrbase
method
two
fi
time
sensit
convent
viru
diagnost
method
cultur
antigen
detect
serolog
assay
detect
respiratori
virus
benefi
appli
particularli
adult
elderli
peopl
might
smaller
nasopharyng
viral
load
children
moreov
respiratori
virus
detect
readili
pcr
develop
sever
multiplex
assay
enabl
simultan
detect
diff
erent
virus
use
test
becom
standard
identifi
cation
respiratori
virus
abil
diff
erenti
viral
bacteri
pneumonia
could
import
manag
implic
despit
advanc
diagnost
test
still
fail
identifi
caus
agent
mani
aff
ect
individu
result
variabl
use
distinguish
viral
bacteri
pneumonia
tabl
howev
clinic
algorithm
exist
discern
clearli
caus
pneumonia
absenc
perhap
surpris
view
probabl
import
interact
virus
bacteria
pathogenesi
pneumonia
respiratori
virus
usual
follow
season
pattern
activ
like
caus
pneumonia
time
epidem
respiratori
syncyti
viru
typic
happen
everi
everi
year
late
autumn
rhinoviru
epidem
aris
autumn
spring
wherea
infl
uenza
peak
seen
late
autumn
earli
winter
sever
virus
cocircul
specifi
c
time
year
even
highest
epidem
peak
one
viru
although
viral
pneumonia
recognis
increasingli
adult
still
seem
typic
children
especi
infant
younger
year
accord
british
thorac
societi
fever
higher
respiratori
rate
greater
breath
per
min
chest
recess
suggest
bacteri
rather
viral
pneumonia
comparison
young
age
wheez
fever
less
strike
chest
recess
suggest
viral
caus
howev
clinic
sign
symptom
viral
bacteri
pneumonia
highli
variabl
overlap
fore
reli
importantli
typic
pneumococc
pneumonia
sudden
onset
high
fever
chill
pleurit
chest
pain
lobar
infi
ltrate
leucocytosi
one
part
rang
bacteri
pneumonia
whitebloodcel
count
concentr
serum
creactiv
protein
procalcitonin
variabl
studi
wide
children
adult
communityacquir
pneumonia
gener
biomark
rais
signifi
cantli
individu
bacteri
pneumonia
compar
patient
viral
pneumonia
tabl
although
none
suffi
cient
sensit
specifi
citi
use
isol
use
procalcitonin
clinic
practic
identifi
bacteri
infect
help
guid
antimicrobi
treatment
focu
mani
studi
substanc
increas
within
h
onset
bacteri
infect
halv
daili
infect
control
context
pneumonia
concentr
procalcitonin
greater
support
bacteri
infect
wherea
repeatedli
low
amount
suggest
bacteri
infect
unlik
howev
exact
role
procalcitonin
manag
pneumonia
still
subject
ongo
discuss
debat
recommend
american
thorac
societi
diagnosi
pneumonia
made
basi
chest
radiographi
interstiti
infi
ltrate
chest
radiograph
gener
believ
suggest
viral
caus
pneumonia
alveolar
infi
ltrate
indic
bacteri
caus
fi
gure
howev
bacteria
virus
alon
togeth
induc
broad
rang
chest
radiograph
chang
alter
help
specifi
c
case
confi
rm
microbi
caus
pneumonia
one
studi
bacteri
infect
note
children
alveolar
infi
ltrate
wherea
bacteri
pneumonia
alveolar
infi
ltrate
children
viral
pneumonia
alveolar
chang
children
bacteraem
pneumococc
pneumonia
alveolar
infi
ltrate
record
interstiti
infi
ltrate
alon
eight
multilob
diseas
variou
case
viral
pneumonia
report
half
adult
communityacquir
pneumonia
thorac
ct
indic
treebud
opac
multifoc
consolid
groundglass
opac
adult
viral
pneumonia
without
evid
possibl
concomit
bacteri
infect
howev
viral
caus
never
suggest
radiologist
intuit
bacteri
pneumonia
respond
appropri
antibacteri
treatment
viral
pneumonia
studi
children
admit
communityacquir
pneumonia
median
durat
fever
h
onset
antibiot
treatment
diff
erenc
record
diagnos
viral
bacteri
pneumonia
howev
children
mix
viral
bacteri
infect
becam
afebril
longer
period
undetect
bacteri
coinfect
probabl
account
respons
antibacteri
treatment
patient
appar
viral
pneumonia
communityacquir
pneumonia
dynam
situat
biomark
infi
ltrate
chest
radiograph
snapshot
activ
state
find
followup
studi
h
might
total
diff
erent
identifi
ed
nine
studi
communityacquir
pneumonia
episod
viral
caus
search
pcr
investig
viru
cultur
antigen
detect
also
use
seven
studi
undertaken
develop
countri
two
develop
countri
evid
viral
infect
record
rang
case
preval
communityacquir
pneumonia
associ
respiratori
syncyti
viru
infl
uenza
virus
parainfl
uenza
virus
adenoviru
similar
report
studi
convent
diagnost
approach
use
exact
number
diff
erent
virus
diffi
cult
compar
one
studi
anoth
sever
techniqu
appli
serolog
assay
alon
use
evid
viral
caus
obtain
children
communityacquir
pneumonia
respiratori
syncyti
viru
domin
pcr
increas
detect
rhinovirus
enterovirus
newli
describ
virus
human
bocaviru
record
case
human
metapneumoviru
coronavirus
seen
children
one
studi
prospect
studi
finland
overal
probabl
caus
pneumonia
record
children
bacteri
infect
viral
infect
comprehens
studi
virolog
perspect
search
virus
children
pneumonia
period
preval
viral
infect
respiratori
syncyti
viru
rhinovirus
human
bocaviru
human
meta
pneumo
viru
parainfl
uenza
virus
common
agent
mani
research
focus
role
singl
respiratori
virus
caus
childhood
communityacquir
pneumonia
studi
sole
viru
infect
look
pneumonia
clinic
profi
le
tabl
global
respiratori
syncyti
viru
continu
major
caus
viral
agent
pneumonia
children
could
predomin
viral
caus
sever
pneumonia
popul
advent
pcr
techniqu
rhinovirus
detect
increasingli
childhood
pneumonia
infect
children
admit
hospit
report
seven
studi
pneumonia
howev
role
rhinovirus
pneumonia
still
question
frequent
detect
rhinovirus
asymptomat
individu
mean
preval
strikingli
respiratori
virus
preval
jartti
colleagu
suggest
pcr
like
detect
true
asymptomat
infect
diffi
culti
rhinovirus
pauciti
serolog
test
verifi
acut
infect
immunocompet
individu
rhinovir
clearanc
symptomat
infect
rapid
averag
week
pneumonia
diagnos
children
admit
acut
human
metapneumoviru
respiratori
infect
highest
preval
infant
younger
month
also
record
children
human
bocaviru
infect
studi
thailand
infant
younger
year
admit
pneumonia
human
bocaviru
third
preval
agent
detect
rhinoviru
respiratori
syncyti
viru
account
case
although
role
human
bocaviru
pneumonia
still
clarifi
ed
serolog
evid
suggest
caus
human
infect
novel
igm
igg
enzym
immunoassay
children
high
load
human
bocaviru
nasopharyng
aspir
wheezi
children
viraemia
diagnost
serorespons
human
bocaviru
identifi
ed
serolog
children
communityacquir
pneumonia
itali
although
preval
adenovirusassoci
pneumonia
fairli
low
rang
type
infect
import
recognis
might
induc
sever
fatal
necrotis
pneumonia
especi
serotyp
china
adenoviru
dna
detect
postmortem
pulmonari
tissu
specimen
children
fatal
pneumonia
note
pcr
substanti
sensit
identifi
cation
adenoviru
antigen
detect
human
coronavirus
newli
discov
type
link
communityacquir
pneumonia
children
infect
human
coronaviru
detect
children
adolesc
larg
pneumonia
studi
thailand
identifi
ed
ten
studi
adult
communityacquir
pneumonia
episod
pcr
use
test
respiratori
virus
evid
viral
infect
detect
case
studi
comprehens
array
convent
virolog
method
also
implement
better
defi
ne
role
virus
adult
communityacquir
pneumonia
similar
fi
nding
paediatr
studi
preval
infect
infl
uenza
virus
respiratori
syncyti
viru
parainfl
uenza
virus
adenoviru
compar
valu
record
convent
diagnost
method
alon
serolog
techniqu
use
four
studi
evid
viral
communityacquir
pneumonia
note
patient
use
pcr
augment
detect
virus
diffi
cult
identifi
convent
method
includ
rhinovirus
human
coronavirus
human
metapneumoviru
result
overal
preval
respiratori
viral
infect
pcr
studi
gener
higher
studi
pcr
implement
full
set
test
fi
nding
three
report
suggest
third
adult
case
communityacquir
pneumonia
associ
viral
infect
research
focus
role
specifi
c
respiratori
virus
adult
communityacquir
pneumonia
respiratori
syncyti
viru
recognis
increasingli
caus
ill
adult
roughli
elderli
patient
admit
pneumonia
usa
infect
associ
viru
infect
respiratori
syncyti
viru
link
substanti
mortal
sever
outbreak
sever
respiratori
diseas
includ
fatal
pneumonia
elderli
resid
nurs
home
associ
rhinovirus
adenovirus
implic
pneumoniarel
admiss
basic
militari
traine
outbreak
pneumonia
associ
adenoviru
serotyp
report
search
systemat
coronavirus
detect
sampl
small
proport
adult
pneumonia
patient
clinic
ill
indistinguish
individu
communityacquir
pneumonia
associ
micro
organ
asymptomat
control
also
human
coronaviru
infect
infect
human
metapneumoviru
aris
throughout
adulthood
outbreak
viral
infect
associ
fatal
outcom
report
longterm
care
facil
patient
admit
human
metapneumoviru
infect
chest
radiograph
infi
ltrate
requir
ventilatori
support
die
human
bocaviru
uncommon
caus
pneumonia
adult
part
surveil
project
thailand
viru
detect
fi
adult
age
year
older
admit
pneumonia
one
control
without
febril
respiratori
ill
sar
coronaviru
caus
sever
respiratori
infect
peopl
led
death
third
patient
sar
becam
critic
ill
pneumonia
lung
injuri
aros
individu
infect
viru
critic
ill
patient
contrast
viral
pneumonia
children
fairli
well
protect
sever
ill
sinc
novemb
avian
infl
uenza
viru
caus
human
infect
casefat
proport
multiorgan
failur
usual
develop
within
week
onset
ill
lymphopenia
thrombocytopenia
rais
concentr
aminotransferas
creatinin
almost
patient
avian
infl
uenza
develop
pneumonia
caus
death
typic
progress
respiratori
failur
sinc
march
pandem
infl
uenza
viru
spread
countri
world
caus
death
usa
alon
million
peopl
infect
australia
rate
admiss
per
popul
critic
ill
aros
commonli
adult
median
age
year
rare
older
year
half
patient
critic
ill
viral
pneumon
acut
respiratori
distress
syndrom
germani
pneumonia
diagnos
patient
pandem
viru
infect
half
admit
uk
patient
chest
radiograph
fi
nding
consist
pneumonia
median
age
patient
pneumonia
year
poor
outcom
viru
infect
record
pregnant
women
indigen
popul
individu
substanti
obes
seriou
comorbid
chest
radiograph
infi
ltrate
sar
infect
usual
interstiti
patchi
bilater
drew
colleagu
review
eight
studi
total
case
respiratori
viral
infect
detect
mostli
convent
techniqu
research
note
dual
viral
infect
case
detect
sever
virus
fairli
high
proport
case
featur
pneumonia
aetiolog
studi
pcr
use
particular
childhood
pneumonia
two
three
virus
detect
children
specifi
calli
human
bocaviru
detect
frequent
associ
respiratori
virus
thai
pneumonia
studi
children
younger
year
human
bocaviru
infect
coinfect
virus
combin
human
bocaviru
rhinoviru
typic
dual
infect
comprehens
virolog
studi
childhood
pneumonia
two
virus
detect
pneumonia
episod
three
virus
record
nine
case
human
bocaviru
associ
virus
episod
follow
infl
uenza
virus
respiratori
syncyti
viru
anoth
studi
children
human
bocaviru
infect
coinfect
anoth
viru
serolog
evid
acut
human
bocaviru
infect
clinic
relev
detect
sever
virus
pneumonia
associ
sever
ill
uncertain
viralvir
interact
vivo
poorli
understood
virus
might
interact
indirectli
directli
result
complement
inhibit
children
pneumonia
caus
coinfect
human
bocaviru
virus
wheez
viral
pneumonia
associ
sole
pathogen
one
studi
viral
coinfect
associ
sever
pneumonia
singl
infect
rate
admiss
look
interest
grown
respect
interact
bacteria
virus
pathogenesi
pneumonia
evid
cell
cultur
ecolog
postmortem
clinic
studi
support
area
interest
favour
hypothesi
viral
infect
follow
secondari
bacteri
infect
research
reassess
data
infl
uenza
pandem
suggest
death
period
probabl
result
secondari
bacteri
pneumonia
fi
nding
contrast
avian
pneumonia
seem
primarili
viral
infect
patient
pandem
infect
secondari
bacteri
infect
develop
case
evid
probabl
mix
viralbacteri
infect
record
case
communityacquir
pneumonia
children
surprisingli
typic
combin
streptococcu
pneumonia
variou
respiratori
virus
develop
countri
virus
bacteria
detect
directli
lung
aspir
sampl
children
pneumonia
studi
gambia
children
evid
pneumococc
communityacquir
pneumonia
also
evid
respiratori
viru
infect
shown
viru
cultur
serolog
test
studi
nigeria
virolog
analysi
done
children
communityacquir
pneumonia
evid
viral
infect
ten
also
blood
cultur
posit
bacteria
usual
staphylococcu
aureu
furthermor
ten
case
measlesassoci
communityacquir
pneumonia
bacteraemia
mix
viralbacteri
infect
adult
communityacquir
pneumonia
seem
report
less
frequent
children
one
studi
viral
bacteri
pathogen
note
case
anoth
investig
evid
mix
viral
bacteri
infect
report
patient
median
age
year
frequent
combin
rhinoviru
plu
strep
pneumonia
infl
uenza
plu
strep
pneumonia
undoubtedli
detect
sever
pathogen
note
frequent
elabor
diagnost
test
use
part
pneumonia
aetiolog
studi
presum
viral
infect
preced
bacteri
infect
like
continu
underestim
true
incid
viralbacteri
coinfect
diffi
culti
detect
earlier
infect
evid
albeit
spars
suggest
mix
infect
could
induc
sever
infl
ammatori
clinic
diseas
individu
bacteri
viral
infect
concomit
infl
uenza
viru
staph
aureu
infect
caus
sever
fatal
pneumonia
children
adult
moreov
one
pneumonia
studi
half
children
treatment
failur
evid
mix
viralbacteri
infect
similarli
adult
rhinoviruspneumococc
infl
uenzabacteri
pneumonia
coinfect
associ
sever
pneumonia
rais
mortal
detect
strep
pneumonia
nasopharynx
patient
pandem
infect
predict
sever
diseas
outcom
postmortem
studi
provid
direct
evid
viral
caus
pneumonia
descript
characterist
lung
histopatholog
mani
diff
erent
respiratori
virus
detect
lung
tissu
case
report
larger
seri
children
die
seriou
respiratori
infect
brazil
use
immunohistochem
techniqu
aid
detect
virus
lung
tissu
bronchopneumonia
interstiti
pneumon
predominantli
respiratori
syncyti
viru
infl
uenza
b
virus
adenoviru
parainfl
uenza
virus
type
anoth
studi
mexico
pcr
detect
respiratori
syncyti
viru
lung
tissu
children
die
pneumonia
archiv
lung
tissu
children
die
pneumonia
south
china
sampl
adenoviru
detect
pcr
immunohistochemistri
rhinoviru
infect
lung
also
shown
histopatholog
natur
histopatholog
chang
viral
pneumonia
vari
possibl
indic
diff
erenc
viral
infect
comorbid
gener
interstiti
pneumon
lymphocyt
infi
ltration
seen
viral
pneumon
fatal
case
pneumonia
caus
respiratori
syncyti
viru
infect
postmortem
evid
show
infect
bronchial
alveolar
epithelium
cell
around
bronchiol
alveolar
interstitium
alveolar
macrophag
monocyt
lymphocyt
also
seen
frequent
around
bronchiol
rhinoviru
pneumonia
hyperplasia
desquam
alveolarlin
cell
immunohistochem
localis
rhinovir
antigen
alveolar
epitheli
cell
macrophag
seen
fatal
case
human
metapneumoviru
pneumonia
patholog
analysi
indic
bilater
haemorrhag
bronchopneumonia
histopatholog
fi
nding
fatal
case
sar
avian
infect
quit
similar
characteris
diff
use
alveolar
damag
desquam
pneumocyt
oedema
hyalinemembran
format
diff
use
alveolar
damag
also
record
lung
peopl
die
pandem
infect
fi
gure
furthermor
necrotis
bronchiol
diff
use
alveolar
damag
alveolar
haemorrhag
alveolar
septal
oedema
hyalin
membran
hyperplasia
type
pneumocyt
necrosi
bronchiolar
wall
note
histopatholog
evid
bacteri
coinfect
report
fatal
case
patient
communityacquir
pneumonia
includ
evid
viral
infect
need
treat
antibiot
date
clear
consensu
exist
issu
expert
recommend
patient
pneumonia
receiv
antibiot
treatment
exclus
presenc
bacteri
infect
imposs
recommend
british
thorac
societi
antibiot
treatment
withheld
young
children
mild
ill
viral
infect
like
far
know
one
randomis
placebocontrol
studi
done
investig
need
antibiot
treatment
childhood
communityacquir
pneumonia
children
clinic
signifi
cant
effi
caci
antibiot
record
studi
children
fairli
mild
diseas
investig
undertaken
epidem
respiratori
syncyti
viru
particip
probabl
pneumonia
caus
viru
randomis
placebocontrol
trial
antibiot
treatment
pneumonia
unlik
happen
ethic
concern
opportun
current
limit
clinic
practic
use
antivir
treatment
pneumonia
tabl
neuraminidas
inhibitor
oseltamivir
zanamivir
develop
establish
role
earli
treatment
infl
uenza
b
infect
children
adult
neuraminidas
inhibitor
reduc
median
time
resolut
symptom
day
administ
within
h
onset
symptom
importantli
earli
use
neuraminidas
inhibitor
reduc
develop
complic
pneumonia
infecti
diseas
societi
america
extend
treatment
neuraminidas
inhibitor
admit
infl
uenza
patient
whose
onset
symptom
h
present
select
appropri
antivir
treat
infl
uenza
made
basi
relev
suscept
data
emerg
pandem
viru
season
viru
develop
resist
oseltamivir
treatment
either
zanamivir
amantadin
rimantidin
recommend
wherea
season
viru
resist
amantadin
rimantidin
subtyp
inform
unavail
zanamivir
combin
oseltamivir
rimantadin
recommend
pandem
viru
remain
suscept
neuraminidas
inhibitor
oseltamivir
use
wide
treatment
pneumonia
caus
viru
although
resist
oseltamivir
report
peopl
pandem
viru
infect
larg
restrict
immunocompromis
individu
isol
still
suscept
zanamivir
intraven
use
peramivir
zanamivir
could
lifesav
critic
ill
patient
infl
uenza
experi
antivir
communityacquir
pneumonia
caus
virus
infl
uenza
scarc
exist
knowledg
mainli
case
report
treatment
studi
immunosuppress
patient
ribavirin
broad
antivir
rang
includ
respiratori
syncyti
viru
human
metapneumoviru
parainfl
uenza
infl
uenza
virus
effi
caci
ribavirin
aerosol
treatment
bronchiol
pneumonia
caus
respiratori
syncyti
viru
infect
modest
best
intraven
ribavirin
could
consid
treatment
sever
pneumonia
caus
infect
respiratori
syncyti
viru
human
metapneumoviru
parainfl
uenza
viru
basi
experi
immunosuppress
patient
new
antivir
agent
develop
respiratori
syncyti
viru
infect
includ
small
interf
rna
sever
case
studi
immunocompromis
patient
clinic
effi
caci
cidofovir
shown
sever
adenoviru
pneumonia
cidofovir
consid
treatment
new
adenoviru
subtyp
pneumonia
research
report
success
manag
ment
human
metapneumoviru
pneumonia
combin
intraven
ribavirin
immuno
globulin
varicella
pneumonia
treat
aciclovir
use
corticosteroid
treatment
viral
communityacquir
pneumonia
controversi
vari
accord
caus
viru
ineff
ectiv
agent
treatment
respiratori
syncyti
viru
infect
well
establish
manag
sar
inconclus
result
report
treatment
studi
possibl
harm
indic
four
trial
highdos
corticosteroid
administ
third
patient
pandem
viru
infect
use
agent
recommend
prolong
viral
shed
season
infl
uenza
increas
mortal
avian
possibl
pandem
viru
infect
hand
data
suggest
corticosteroid
augment
outcom
pneumonia
caus
infect
varicellazost
viru
combin
aciclovir
hantaviru
possibl
prevent
viral
communityacquir
pneumonia
limit
infl
uenza
vaccin
use
sinc
mid
establish
role
prevent
infl
uenza
b
viru
infect
importantli
inactiv
infl
uenza
vaccin
eff
ectiv
young
children
includ
younger
year
pandem
monoval
vaccin
viru
develop
activ
use
could
play
part
cours
initi
pandem
wave
countrieseg
finland
fatal
case
record
addit
vaccin
infl
uenza
b
viru
infect
prevent
prophylact
use
neuraminidas
inhibitor
sever
respiratori
syncyti
viru
infect
highrisk
neonat
prevent
success
palivizumab
humanis
monoclon
antibodi
administ
respiratori
syncyti
viru
epidem
agent
shown
prevent
admiss
relat
respiratori
syncyti
viru
prematur
infant
sinc
sever
type
vaccin
respiratori
syncyti
viru
develop
without
success
liveattenu
vaccin
produc
revers
genet
clinic
studi
pneumonia
caus
adenoviru
type
prevent
militari
traine
oral
vaccin
effi
caci
unfortun
confl
ict
manufactur
process
stop
product
pneumococc
conjug
vaccin
shown
prevent
third
viral
pneumonia
case
studi
south
africa
probabl
prevent
superimpos
bacteri
coinfect
despit
mani
advanc
studi
still
need
better
understand
role
virus
caus
pathogenesi
communityacquir
pneumonia
increas
avail
molecular
diagnost
method
enabl
us
evalu
understand
viral
pneumonia
reassess
exist
dogma
clarifi
cation
need
role
bacterialvir
interact
pathogenesi
pneumonia
import
virus
pneumonia
pathogen
world
widespread
implement
h
infl
uenza
type
b
pneumococc
conjug
vaccin
also
examin
region
diff
erenc
caus
pneumonia
need
urgent
particularli
obtain
addit
data
develop
countri
detail
understand
viral
caus
communityacquir
pneumonia
guid
antivir
drug
vaccin
develop
